The FDA has approved a long-acting proton pump inhibitor (PPI) for once-daily treatment of gastroesophageal reflux disease, or GERD, according to an announcement by the drugmaker. Kapidex (generic name: dexlansoprazole) was approved for healing all grades of erosive esophagitis for up to eight weeks, for maintaining healing of erosive esophagitis for up to six months, and for treating heartburn associated with symptomatic nonerosive GERD for four weeks, said Takeda Pharmaceuticals.
The company said the prescription drug is designed to provide two separate releases of the medication, a first peak one to two hours after administration and a second peak four to five hours later. The capsules may be taken with or without food. PPIs reduce acid production by turning off many of the acid pumps in the stomach.